UBS Group
PASW

UBS Group’s Ping An Biomedical PASW Stock Holding History

UBS Group’s Portfolio PASW Stock Details PASW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.14K Buy
16,239
+11,515
+244% +$2.4K ﹤0.01% 9347
2025
Q4 		$2.37K Buy
4,724
+4,651
+6,371% +$3.1K ﹤0.01% 9324
2025
Q3 		$91 Buy
+73
New +$108 ﹤0.01% 9934

Other funds holding PASW

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

UBS Group's PASW Position: Q1 2026 in Review

UBS Group increased its Ping An Biomedical (PASW) stake by 244% in Q1 2026, buying an estimated $2.4K and bringing the position to 16,239 shares worth $2.14K. The position accounts for ﹤0.01% of the portfolio, ranked #9347.

UBS Group first reported a position in PASW in Q3 2025 and has held it in 3 quarters since. The position peaked at $2.37K in Q4 2025. 4 funds tracked by Wall St. Rank hold PASW as of Q1 2026.

  • UBS Group held 16,239 shares of Ping An Biomedical worth $2.14K as of Q1 2026.
  • UBS Group bought 11,515 Ping An Biomedical shares in Q1 2026, an estimated $2.4K.
  • Ping An Biomedical made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #9347 holding.
  • UBS Group first reported a position in Ping An Biomedical in Q3 2025 and has held it in 3 quarters since.
  • UBS Group's Ping An Biomedical position peaked at $2.37K in Q4 2025.
  • 4 funds tracked by Wall St. Rank held Ping An Biomedical as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.